Omalizumab controls surface phenotypes of dendritic cells and monocytes in asthma.

ABSTRACT:

Background

Omalizumab can provide clinical benefits to a fraction of moderate-to-severe asthma patients. However, the mechanisms of action of omalizumab have not been fully understood.

Objective

This study investigated whether omalizumab could affect the frequency and surface phenotypes of blood circulating dendritic cell (DC) and monocyte subsets, which could be associated with the mechanisms of action of omalizumab.

Methods

Longitudinal analyses of the frequency and surface phenotypes of DC and monocyte subsets in fresh whole blood of moderate-to-severe asthma patients (n = 45, 34 with response and 11 without response, from baseline to week 26) were performed by flow cytometry. Nonasthmatic subjects (n = 22) were also used as controls at baseline.

Results

Oma

SUBMITTER: Yang A 

PROVIDER: S-EPMC12281943 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature